Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dyadic International (DYAI)

Dyadic International (DYAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,732
  • Shares Outstanding, K 36,188
  • Annual Sales, $ 3,500 K
  • Annual Income, $ -5,810 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.24
  • Price/Sales 10.35
  • Price/Cash Flow N/A
  • Price/Book 13.88
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.24
  • Most Recent Earnings $-0.06 on 11/12/25
  • Next Earnings Date 03/25/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 65.60%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Expected Move (DTE 22) 0.0000 (0.00%)
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A
  • Expected Range 0.9874 to 0.9874

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.03
  • Number of Estimates 1
  • High Estimate -0.03
  • Low Estimate -0.03
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8010 +22.91%
on 12/15/25
1.1385 -13.53%
on 12/01/25
+0.0745 (+8.19%)
since 11/24/25
3-Month
0.8010 +22.91%
on 12/15/25
1.3460 -26.86%
on 10/01/25
-0.1630 (-14.20%)
since 09/24/25
52-Week
0.7110 +38.47%
on 08/15/25
2.1434 -54.07%
on 01/07/25
-0.7555 (-43.42%)
since 12/24/24

Most Recent Stories

More News
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets

JUPITER, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing...

DYAI : 0.9845 (-0.29%)
Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins

JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI) , a global biotechnology company producing precision-engineered, animal-free proteins and enzymes...

DYAI : 0.9845 (-0.29%)
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

RALEIGH, NC / ACCESS Newswire / December 8, 2025 / iAccess Alpha's Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and...

MOB : 6.36 (-3.20%)
BOSC : 4.65 (+1.75%)
STRT : 79.98 (-0.24%)
ELWT : 5.02 (unch)
FLUX : 1.4000 (+2.94%)
DGX.VN : 3.680 (-1.60%)
BCHT.TO : 1.09 (+3.81%)
GAME : 0.4499 (+2.72%)
WYY : 5.70 (-4.68%)
ACNT : 15.93 (-0.93%)
DCGO : 0.9157 (+4.04%)
VELO : 14.43 (-3.22%)
Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets

JUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing precision-engineered, animal-free proteins...

DYAI : 0.9845 (-0.29%)
iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

RALEIGH, NC / ACCESS Newswire / December 1, 2025 / iAccess Alpha's Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and...

MOB : 6.36 (-3.20%)
BOSC : 4.65 (+1.75%)
STRT : 79.98 (-0.24%)
ELWT : 5.02 (unch)
DGX.VN : 3.680 (-1.60%)
BCHT.TO : 1.09 (+3.81%)
GAME : 0.4499 (+2.72%)
ACNT : 15.93 (-0.93%)
WYY : 5.70 (-4.68%)
DCGO : 0.9157 (+4.04%)
DGXX : 2.70 (-1.82%)
SCNX : 0.5355 (-7.64%)
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

Completed strategic pivot from R&D focus to commercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relations...

DYAI : 0.9845 (-0.29%)
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered,...

DYAI : 0.9845 (-0.29%)
Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025

JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global...

DYAI : 0.9845 (-0.29%)
Dyadic International Achieves Milestone Payments and Compliance

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

DYAI : 0.9845 (-0.29%)
Dyadic International (DYAI) Receives a Buy from Craig-Hallum

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Dyadic International today. The company’s shares closed yesterday at $1.18.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

DYAI : 0.9845 (-0.29%)

Business Summary

Dyadic International, Inc. is a leading genomics company with the groundbreaking technology that brings nature to the marketplace. Dyadic is poised to become a global leader in proteomics through the discovery, development, and manufacturing of novel products derived from the DNA of complex living organisms...

See More

Key Turning Points

3rd Resistance Point 1.0562
2nd Resistance Point 1.0281
1st Resistance Point 1.0063
Last Price 0.9845
1st Support Level 0.9564
2nd Support Level 0.9283
3rd Support Level 0.9065

See More

52-Week High 2.1434
Fibonacci 61.8% 1.5962
Fibonacci 50% 1.4272
Fibonacci 38.2% 1.2582
Last Price 0.9845
52-Week Low 0.7110

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar